{"id":"W3172086766","doi":"10.1200/jco.2021.39.15_suppl.lba4","title":"Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Hazard ratio; Taxane; Progression-free survival; Urology; Internal medicine; Oncology; Clinical endpoint; Abiraterone acetate; Prostate; Response Evaluation Criteria in Solid Tumors; Confidence interval; Phases of clinical research; Cancer; Nuclear medicine; Randomized controlled trial; Clinical trial; Androgen deprivation therapy; Chemotherapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001738262,0.001570864,0.002028924,0.0004878813,0.0004785193,0.001048653,0.001071815,0.001227152,0.004251768],"category_scores_gemma":[0.0008789511,0.0006288053,0.001421664,0.0004288602,0.001022575,0.0006251703,0.0004065752,0.002542252,0.001275706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001040131,"about_ca_system_score_gemma":0.002381311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002165404,"about_ca_topic_score_gemma":0.004157663,"domain_scores_codex":[0.9995545,0.0002344876,0.00001574076,0.00006232435,0.00003619787,0.00009675196],"domain_scores_gemma":[0.9993268,0.00009531459,0.0001082483,0.00005183716,0.0000499991,0.0003676931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7552316,0.08294469,0.006498007,0.001022663,0.001716601,0.0002791511,0.000372321,0.003289295,0.04533223,0.0004941645,0.004885774,0.09793349],"study_design_scores_gemma":[0.5506589,0.436411,0.006729107,0.00003003056,0.0003964753,0.0001964462,0.00005266695,0.0008755631,0.002138313,0.0002274739,0.002264292,0.00001966365],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880657,0.002567193,0.0008533891,0.0005761822,0.000189579,0.004052693,0.001126993,0.0001554384,0.002412782],"genre_scores_gemma":[0.9847265,0.001844119,0.002027595,0.001346293,0.0002004368,0.00379746,0.002219712,0.0000514797,0.003786379],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004251768,"threshold_uncertainty_score":0.01422364,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1265274024230974,"score_gpt":0.5251846662483957,"score_spread":0.3986572638252982,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}